DE602004006895D1 - Verfahren zur behandlung von multipler sklerose - Google Patents
Verfahren zur behandlung von multipler skleroseInfo
- Publication number
- DE602004006895D1 DE602004006895D1 DE602004006895T DE602004006895T DE602004006895D1 DE 602004006895 D1 DE602004006895 D1 DE 602004006895D1 DE 602004006895 T DE602004006895 T DE 602004006895T DE 602004006895 T DE602004006895 T DE 602004006895T DE 602004006895 D1 DE602004006895 D1 DE 602004006895D1
- Authority
- DE
- Germany
- Prior art keywords
- multiple sclerosis
- meca
- treating multiple
- a3rag
- apnea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 229940122614 Adenosine receptor agonist Drugs 0.000 abstract 3
- 239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 3
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 abstract 1
- LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 abstract 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 abstract 1
- 101150046889 ADORA3 gene Proteins 0.000 abstract 1
- 208000008784 apnea Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preliminary Treatment Of Fibers (AREA)
- Spinning Or Twisting Of Yarns (AREA)
- Treatment Of Fiber Materials (AREA)
- Sewing Machines And Sewing (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53271203P | 2003-12-29 | 2003-12-29 | |
| US532712P | 2003-12-29 | ||
| PCT/IL2004/001160 WO2005063246A1 (en) | 2003-12-29 | 2004-12-23 | Method for treatment of multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004006895D1 true DE602004006895D1 (de) | 2007-07-19 |
| DE602004006895T2 DE602004006895T2 (de) | 2008-01-31 |
Family
ID=34738826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004006895T Expired - Fee Related DE602004006895T2 (de) | 2003-12-29 | 2004-12-23 | Verfahren zur behandlung von multipler sklerose |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7465715B2 (de) |
| EP (1) | EP1699459B1 (de) |
| JP (1) | JP2007517019A (de) |
| CN (1) | CN100423723C (de) |
| AT (1) | ATE363907T1 (de) |
| DE (1) | DE602004006895T2 (de) |
| DK (1) | DK1699459T3 (de) |
| ES (1) | ES2287804T3 (de) |
| PL (1) | PL1699459T3 (de) |
| WO (1) | WO2005063246A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| EP1817079B1 (de) | 2004-12-02 | 2008-07-30 | Can-Fite Biopharma Ltd. | Behandlung von entzündungen |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| ATE502640T1 (de) | 2006-01-26 | 2011-04-15 | Us Gov Health & Human Serv | Allosterische a3-adenosin-rezeptormodulatoren |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| JP5373599B2 (ja) * | 2006-04-21 | 2013-12-18 | ノバルティス アーゲー | アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体 |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (de) | 2006-07-13 | 2008-02-20 | Novartis AG | Purinderivate als A2a Agonisten |
| EP1903044A1 (de) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosinderivate als Agonisten des A2A-Rezeptors |
| BRPI0718792A2 (pt) * | 2006-11-10 | 2013-12-03 | Novartis Ag | Compostos orgânicos |
| EP2137202B1 (de) | 2007-03-14 | 2017-06-21 | Can-Fite Biopharma Ltd. | Verfahren zur herstellung von ib-meca |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| US9199102B2 (en) * | 2009-07-21 | 2015-12-01 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| IL200753A (en) | 2009-09-06 | 2015-06-30 | Can Fite Biopharma Ltd | Pharmaceutical preparation containing ib – meca for the treatment of psoriasis |
| EP3124970A1 (de) * | 2011-04-22 | 2017-02-01 | Kyoto University | Verwendung des basischen myelinproteins als neuartiger genetischer faktor für rheumatoide arthritis |
| UA117095C2 (uk) | 2011-12-22 | 2018-06-25 | Аліос Біофарма, Інк. | Нуклеозидна сполука або її фармацевтично прийнятна сіль |
| CN104159589A (zh) * | 2012-01-23 | 2014-11-19 | 坎-菲特生物药物有限公司 | 肝脏状况的治疗 |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA201892008A1 (ru) * | 2016-04-21 | 2019-06-28 | Астросайт Фармасьютикалс, Инк. | Соединения и способы лечения неврологических и сердечно-сосудистых состояний |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5773423A (en) | 1993-07-13 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| WO1997033879A1 (en) * | 1996-03-15 | 1997-09-18 | Merck & Co., Inc. | Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6303619B1 (en) * | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| CZ294538B6 (cs) * | 2002-12-30 | 2005-01-12 | Ústav Experimentální Botaniky Akademie Vědčeské Re | Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
-
2004
- 2004-12-23 US US10/521,193 patent/US7465715B2/en not_active Expired - Fee Related
- 2004-12-23 JP JP2006546475A patent/JP2007517019A/ja not_active Withdrawn
- 2004-12-23 CN CNB2004800393344A patent/CN100423723C/zh not_active Expired - Fee Related
- 2004-12-23 DK DK04806691T patent/DK1699459T3/da active
- 2004-12-23 ES ES04806691T patent/ES2287804T3/es active Active
- 2004-12-23 AT AT04806691T patent/ATE363907T1/de not_active IP Right Cessation
- 2004-12-23 EP EP04806691A patent/EP1699459B1/de not_active Not-in-force
- 2004-12-23 PL PL04806691T patent/PL1699459T3/pl unknown
- 2004-12-23 DE DE602004006895T patent/DE602004006895T2/de not_active Expired - Fee Related
- 2004-12-23 WO PCT/IL2004/001160 patent/WO2005063246A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ATE363907T1 (de) | 2007-06-15 |
| PL1699459T3 (pl) | 2007-12-31 |
| WO2005063246A1 (en) | 2005-07-14 |
| US20060142237A1 (en) | 2006-06-29 |
| DK1699459T3 (da) | 2007-10-08 |
| CN100423723C (zh) | 2008-10-08 |
| EP1699459B1 (de) | 2007-06-06 |
| JP2007517019A (ja) | 2007-06-28 |
| DE602004006895T2 (de) | 2008-01-31 |
| CN1901915A (zh) | 2007-01-24 |
| ES2287804T3 (es) | 2007-12-16 |
| US7465715B2 (en) | 2008-12-16 |
| EP1699459A1 (de) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE363907T1 (de) | Verfahren zur behandlung von multipler sklerose | |
| MY146986A (en) | Methods for treating interleukin-6 related diseases | |
| BRPI0418112A (pt) | inibidores de p-38 quinase bicìclico heterocìclicos | |
| ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
| DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
| CY1112281T1 (el) | Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη | |
| SG116667A1 (en) | Internal riser inspection system, apparatus and methods of using same. | |
| AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| EA200501817A1 (ru) | Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| CY1110775T1 (el) | Υποκατεστημενα αμιδια του θειενοπυρρολιου του καρβοξυλικου οξεος, αμιδια της πυρρολοθειαζολης του καρβοξυλικου οξεος και σχετικα αναλογα ως αναστολεις της κινασης i εψιλον της καζεϊνης | |
| ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| DK1545537T3 (da) | Alfa-7-nikotinreceptoragonister og statiner i kombination | |
| MX2007005525A (es) | Tratamiento terapeutico de resorcion ose acelerada. | |
| WO2000053148A3 (en) | Methods and compositions for treating erectile dysfunction | |
| WO2003105891A3 (en) | USE OF HEC1 ANTAGONISTS IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND CANCERS | |
| HUP0401967A2 (hu) | Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására | |
| CA2503286A1 (en) | Compounds for the treatment of tobacco dependence and withdrawal | |
| WO2003094957A3 (en) | Methods of therapy for inducing tolerance | |
| BR0206844A (pt) | Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |